ストックスクリーナーアプリを入手
85.53
0.63%
-0.925
前日終値:
$86.45
開ける：
$86.88
24時間の取引高:
384.81K
Relative Volume:
0.54
時価総額：
$5.46B
収益：
$136.86M
当期純損益:
$-168.69M
株価収益率:
-30.44
EPS:
-2.81
ネットキャッシュフロー:
$-113.49M
1週間 パフォーマンス:
-3.07%
1か月 パフォーマンス:
+36.95%
6か月 パフォーマンス:
+51.22%
1年 パフォーマンス:
+75.14%
1日の値動き範囲:
$84.22
$86.88
1週間の範囲:
$84.22
$89.67
52週間の値動き範囲:
$40.61
$94.80
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
名前
Rhythm Pharmaceuticals Inc
セクター
電話
857-264-4280
住所
222 BERKELEY STREET, BOSTON, MA
RYTM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
85.86 | 5.70B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.01 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.32 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.03 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.94 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-07-07 | 開始されました | Leerink Partners | Outperform |
| 2025-04-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-05 | 再開されました | Stifel | Buy |
| 2025-01-02 | 開始されました | Jefferies | Buy |
| 2024-12-20 | 開始されました | Oppenheimer | Outperform |
| 2024-10-21 | 開始されました | Guggenheim | Buy |
| 2024-09-18 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-17 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-05-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-08-08 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-05 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 繰り返されました | Needham | Buy |
| 2022-03-02 | 再開されました | Stifel | Buy |
| 2022-02-17 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 再開されました | Goldman | Neutral |
| 2021-08-04 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-08-04 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-01-08 | 開始されました | Goldman | Sell |
| 2019-07-12 | アップグレード | Stifel | Hold → Buy |
| 2019-07-08 | 開始されました | Canaccord Genuity | Buy |
| 2019-03-13 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-09-07 | 再開されました | Morgan Stanley | Overweight |
| 2018-06-25 | 繰り返されました | Needham | Buy |
| 2018-06-15 | 繰り返されました | Needham | Buy |
| 2017-10-30 | 開始されました | BofA/Merrill | Buy |
| 2017-10-30 | 開始されました | Needham | Buy |
すべてを表示
Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース
What is Rhythm Pharmaceuticals Inc. company’s growth strategyFree Stock Market Return Analysis - jammulinksnews.com
Rhythm Pharma Gets Price-Target Bump Ups To $129 After Oral Obesity Drug Impresses In Phase 2; Retail Appetite Swells - MSN
What are the latest earnings results for Rhythm Pharmaceuticals Inc.Discover stocks with explosive upside potential - jammulinksnews.com
How strong is Rhythm Pharmaceuticals Inc. company’s balance sheetIdentify breakout stocks before they peak - jammulinksnews.com
When is Rhythm Pharmaceuticals Inc. stock expected to show significant growthPhenomenal trading returns - jammulinksnews.com
Is Rhythm Pharmaceuticals Inc. a growth stock or a value stockFree Stock Market Return Analysis - jammulinksnews.com
Is Rhythm Pharmaceuticals Inc. stock overvalued or undervaluedRapid capital growth - jammulinksnews.com
Published on: 2025-07-27 20:42:04 - jammulinksnews.com
Published on: 2025-07-27 06:42:10 - Metal.it
What drives Rhythm Pharmaceuticals Inc. stock priceTriple-digit wealth increases - PrintWeekIndia
Rhythm Pharmaceuticals Inc. Stock Analysis and ForecastUnstoppable trading performance - PrintWeekIndia
Is Rhythm Pharmaceuticals Inc. a good long term investmentDouble-digit growth - PrintWeekIndia
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire
Rhythm Pharmaceuticals Announces Q2 Earnings Date and Major Conference Appearance - Stock Titan
What analysts say about Rhythm Pharmaceuticals Inc. stockTremendous growth potential - jammulinksnews.com
Should You Invest in This Under-the-Radar Weight Loss Stock? - The Motley Fool
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity - MSN
Why Rhythm Pharmaceuticals Inc. stock is on top investor watchlistsMoney Making Low Risk Plans - beatles.ru
Rhythm Pharmaceuticals Q1 2025 Earnings: IMCIVREE Sales Reach $37.7M, Inventory Impact Affects Revenue, Cash on Hand Reaches $314.5M - AInvest
Rhythm Pharmaceuticals CFO Sells 42,120 Shares - AInvest
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 10 Analysts - Nasdaq
Canaccord Genuity raises Rhythm Pharmaceuticals stock price target on obesity treatment potential - Investing.com Canada
(RYTM) Investment Analysis - news.stocktradersdaily.com
Rhythm Pharmaceuticals stock price target raised to $109 from $95 at BofA - Investing.com Canada
Rhythm Pharmaceuticals’ Promising MC4R Agonist Portfolio: Strong Phase 3 Results and Strategic Market Expansion - TipRanks
Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds - MSN
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given a $110.00 Price Target by Oppenheimer Analysts - MarketBeat
The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter
Rhythm Pharmaceuticals: MC4R Agonists Poised to Transform Obesity Treatment and Drive Market Leadership - AInvest
Rhythm Pharmaceuticals announces public offering of common stock - MSN
Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar? - MSN
Rhythm Pharmaceuticals price target raised to $95 from $72 at Needham - MSN
Rhythm Pharmaceuticals' MC4R Agonists: A Rare Disease Breakthrough with Massive Upside - AInvest
Rhythm Pharmaceuticals: Pioneering a New Era in Rare Obesity Therapies with MC4R Agonists - AInvest
Rhythm Pharmaceuticals says Phase 2 signal trial shows bivamlegon reduces BMI in hypothalamic obesity - MarketScreener
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025 - GlobeNewswire
Rhythm Pharmaceuticals Shares Jump Following Promising Phase 2 Data for Obesity Drug - MSN
Rhythm Pharmaceuticals' Insider Sales: A Pre-Planned Strategy or a Signal for Investors? - AInvest
Rhythm Pharmaceuticals: Insider Sales and Equity Offering Signal Mixed Signals for Investors - AInvest
Rhythm Pharmaceuticals Insider Sales and I-MAB's Capital Raise: Navigating Dilution Risks and Confidence Signals - AInvest
Rhythm Pharmaceuticals: Insider Selling and Valuation in a High-Stakes Biotech Landscape - AInvest
Top 3 Trending Stocks: Ultragenyx Pharmaceutical, Rhythm Pharmaceuticals, and Nurix Therapeutics - AInvest
Rhythm Pharmaceuticals Announces Stock Offering Agreement - TipRanks
Rhythm Pharmaceuticals Inc (RYTM) 財務データ
収益
当期純利益
現金流量
EPS
Rhythm Pharmaceuticals Inc (RYTM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Smith Hunter C | Chief Financial Officer |
Jul 09 '25 |
Sale |
80.48 |
42,120 |
3,389,756 |
116,915 |
| Shulman Joseph | Chief Technical Officer |
Jul 09 '25 |
Option Exercise |
6.80 |
7,969 |
54,189 |
16,478 |
| Shulman Joseph | Chief Technical Officer |
Jul 09 '25 |
Sale |
77.78 |
7,969 |
619,851 |
8,509 |
| German Christopher Paul | Corporate Controller & CAO |
Jul 09 '25 |
Option Exercise |
27.29 |
2,850 |
77,786 |
4,739 |
| German Christopher Paul | Corporate Controller & CAO |
Jul 09 '25 |
Sale |
80.75 |
3,817 |
308,217 |
922 |
| Cramer Pamela J. | Chief Human Resources Officer |
Jul 09 '25 |
Option Exercise |
13.43 |
15,572 |
209,153 |
34,781 |
| Cramer Pamela J. | Chief Human Resources Officer |
Jul 09 '25 |
Sale |
77.13 |
15,572 |
1,201,062 |
19,209 |
0.94%
1.30%
大文字化:
|
ボリューム (24 時間):